CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 6, July 2013
242
AFRICA
The authors acknowledge the participation of all the investigators who partic-
ipated in the study. Ms Michelle Nortje of AstraZeneca Pharmaceuticals was
most helpful in the acquisition of data.
References
1.
Yusuf S, Hawken S, Ounpuu S,
et al.
Effect of potentially modifiable
risk factors associated with myocardial infarction in 52 countries (the
INTERHEART study): case control study.
Lancet
2004;
364
: 937–952.
2.
Kuklina E, Yoon P, Keenan N. Trends in high levels of low-density
lipoprotein cholesterol in the United States, 1999–2006.
J Am Med
Assoc
2009;
302
(19): 2104–2110.
3.
Kotseva K, Wood D, De Backer G,
et al
. EUROASPIRE III: a survey
on the lifestyle, risk factors and use of cardioprotective drug therapies
in coronary patients from 22 European countries.
J Cardiovasc Risk
2009;
16
: 121–137.
4.
Gitt A, Drexel H, Feely J,
et al
. High prevalence of persistent lipid
abnormalities in high-risk patients treated with statins in Europe and
Canada: results of the Dyslipidemia International Study (abstract).
J Am
Coll Cardiol
2009; A372.
5.
Pearson T, Laurora I, Chu H,
et al
. The Lipid Treatment Assessment
Project (L-TAP): a multi-centre survey to evalulate the percentages of
dyslipidemic patients receiving lipid-lowering therapy and achieving
low-density lipoprotein cholesterol goals.
Arch Int Med
2000;
160
:
459–467.
6.
Van Ganse E, Laforest L, Alemao E,
et al
. Lipid-modifying therapy and
attainment of cholesterol goals in Europe: the Return on Expenditure
Achieved for Lipid Therapy (REALITY) study.
Curr Med Res Opin
2005;
21
(9): 1389–1399.
7.
Hermans M, Cabenzas M, StrandbergT,
et al
. Centralized Pan-European
survey on the under-treatment of hypercholesterolemia (CEPHEUS):
overall findings from eight countries.
Curr Med Res Opin
2010;
26
(2):
445–454.
8.
Bandegas J, Lopez-Garcia E, Dallongeville J,
et al
. Achievement of
treatment goals for primary prevention of cardiovascular disease in
clinical practice across Europe: the EURIKA study.
Eur Heart J
2011;
32
: 2143–2152.
9.
Ramjeeth A, Butkow N, Raal F,
et al
. The evaluation of low-density
lipoprotein cholesterol goals achieved in patients with established
cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering
therapy: the South African Not-at-Goal study (SA-NAG).
Cardiovasc
J Afr
2008;
19
(2): 88–94.
10. De Backer G, Ambrosioni E, Borch-Johnsen K,
et al
. European
guidelines on cardiovascular disease prevention in clinical practice.
Third joint task force of European and other societies on cardiovas-
cular disease prevention in clinical practice.
Eur Heart J
2003;
24
:
1601–1610.
11. Third report of the National Cholesterol Education Program (NCEP)
expert panel on detection, evaluation and treatment of high blood
cholesterol in adults (Adult Treatment Panel III); final report.
Circulation
2002;
106
: 3143–3421.
12. Graham I, Atar D, Borch-Johnsen K,
et al
. European guidelines
on cardiovascular disease prevention in clinical practice: execu-
tive summary. Fourth Joint Task Force of the European Society of
Cardiology and other societies on cardiovascular disease prevention in
clinical practice.
Eur Heart J
2007;
28
: 2375–2414.
13. Grundy S, Cleeman J, Merz C,
et al
. National heart, Lung and Blood
Institute: American College of Cardiology Foundation; American
Heart Association. Implications of recent clinical trials for the National
Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation
2004;
110
: 227–239.
14. Raal F, Schamroth C, Blom D, Marx J, Rajput M, Haus M,
et al
.
CEPHEUS SA: a South African survey on the undertreatment of hyper-
cholesterolaemia.
Cardiovasc J Afr
, 2011;
22
(5): 234–240.
15. Beaglehole R, Yach D. Globalisation and the prevention and control
of non-communicable disease: the neglected diseases of adults.
Lancet
2003;
362
(9387): 903–908.
16. Reddy KS. Cardiovascular disease in non-Western countries.
New Engl
J Med
2004;
350
(24): 2438–2440.
17. Sliwa K, Lyons JG, Carrington MJ, Lecour S,
et al
. Different lipid
profiles according to ethnicity in the Heart of Soweto study cohort
of
de novo
presentations of heart disease.
Cardiovasc J Afr
2012;
23
:
389–395.
18. Sliwa K, Wilkinson D, Hanson D,
et al
. Spectrum of heart disease and
risk factors in a black urban population in South Africa (the Heart of
Soweto Study): a cohort study.
Lancet
2008;
371
: 915–922.
19. Steyn K, Sliwa K, Hawken S,
et al
. Risk factors associated with
myocardial infarction in Africa: the INTERHEART Africa study.
Circulation
2005;
112
: 3554–3561.
